Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
Antimicrobial resistant bacteria are present in newborns after just a few hours of life and they help to understand the routes of transmission of antibiotic-resistance genes.
The findings of a new research suggest that different responses to statins can be explained by the variation in the human microbiota.
The findings of a new research illuminate the link between IBS and gut bacteria, and suggest that histamine is a good target for therapies against the condition.
The findings of a new research suggest that during the early maturation, the microbiota would be more likely to be influenced by other microbiotas on a not-too-distant level of maturity.
The results of a new research done in mice suggest that gut bacteria can regulate host physiology by metabolizing vitamin A.
New research in mice suggests that two MACs, L-arabinose and sucrose, have specific effects on gut microbes that may prevent diet-induced obesity.
The findings of a new research show that gut bacteria can become harmful over time by gaining the ability to escape the intestine and persist in other organs where they…
The findings of a new research suggest that changes in the microbial composition of people with COVID-19 could be used as a biomarker of invasion of lung pathogens and dysbiosis…
The findings of a new research may inform strategies for treating intestinal diseases by targeting pathogens without killing beneficial gut bacteria.
Researchers at Harvard Medical School propose to “rejuvenate” a person’s microbiota by collecting stool samples for future treatment of diseases that could be managed with fecal microbial transplantation (FMT).
